(Q24234273)

2

0 references

Keith Wheatley

6

0 references

Katherine Deane

4

0 references

Carl E Clarke

3

object named as

Carl E Clarke

0 references

author name string

van Hilten

5

0 references

Richard Gray

7

0 references

Kelly Handley

8

0 references

Alex Furmston

Cochrane Database of Systematic Reviews

9

0 references

publication date

7 July 2010

0 references

published in

0 references

cites work

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Twelve-month safety of entacapone in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Bromocryptine in levodopa response-losing parkinsonism. A double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

The long-term safety and efficacy of pramipexole in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Low dosages of bromocriptine added to levodopa in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Treatment of the on-off syndrome in Parkinsonism with low dose bromocriptine in combination with levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Bromocriptine and levodopa (with or without carbidopa) in parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Deprenyl in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Subgroup analysis and other (mis)uses of baseline data in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Cabergoline for levodopa-induced complications in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Pergolide for levodopa-induced complications in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Pramipexole for levodopa-induced complications in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Ropinirole for levodopa-induced complications in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

The statistical basis of meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Science, medicine, and the future: Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Bromocriptine for levodopa-induced motor complications in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

[Bromocriptin in the treatment of progressive stages of Parkinson's disease (author's transl)]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Effects of selegiline dosing on motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

1 reference

7 January 2021

Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Effects of bromocriptine on parkinsonism. A nation-wide collaborative double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

The effect of L-Deprenyl on on-off phenomena in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Medical management of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Final report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Studies with bromocriptine. Part 2. Double-blind comparison with levodopa in idiopathic parkinsonism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Double-blind trial of pergolide for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007166.PUB2

7 January 2021